Tibet Cheezheng Tibetan Medicine Co Ltd: Financial Highlights and Recent Developments
Tibet Cheezheng Tibetan Medicine Co Ltd, a prominent player in the pharmaceutical sector, specializes in the development, manufacturing, and marketing of Tibetan medicines. The company is listed on the Shenzhen Stock Exchange and has a market capitalization of 131.6 billion CNH. As of July 27, 2025, the close price of the company’s stock was 24.7 CNH, with a 52-week high of 26.9 CNH on May 11, 2025, and a 52-week low of 18.23 CNH on September 17, 2024. The price-to-earnings ratio stands at 23.44.
Recent Stock Performance and Market Activity
On July 30, 2025, Tibet Cheezheng Tibetan Medicine Co Ltd’s stock reached its price limit, marking the fifth time in the past year that the stock has hit this threshold. This surge is attributed to several factors:
Market Leadership: The company is recognized as a leading enterprise in the Tibetan medicine industry in China. Its core product, the anti-inflammatory patch, holds the top spot in the brand ranking for external applications in bone and muscle system diseases in urban pharmacies across China, maintaining a solid market share.
Expansion Efforts: The company has been actively expanding its product coverage in the Yaxi project area, increasing the local penetration of its Tibetan medicine products. Key products like the anti-inflammatory patch, Qingpeng ointment, and Bai Mai ointment are already available in county-level hospitals and clinics in Mêdog and Milin counties. Future plans include promoting Red Jingtian oral liquid for high-altitude sickness and Shiwu Longdanhua capsules for respiratory system use.
Collaborations and Research: The company collaborates with institutions such as Tibet Agricultural and Animal Husbandry University, Tibet University, and Tibet Plateau Biology Research Institute. These partnerships focus on projects like the “Ecological Cultivation Technology Integration and Demonstration Application of Endangered and Rare Tibetan Medicinal Materials” under the Tibet Autonomous Region’s Science and Technology Plan.
Financial Transactions and Market Sentiment
On July 28, 2025, the company received margin buying of 12.49 million CNH, accounting for 27.74% of the day’s total buy-in amount. The current margin balance stands at 117.14 million CNH, representing 0.89% of the circulating market value, which is below the historical 50% percentile.
Investor Relations and Strategic Focus
The company has been actively engaging with investors, addressing questions about leveraging the Yaxi project to enhance local medical channels and expand the coverage of Tibetan medicine products. The company’s strategic focus includes:
- Local Expansion: Expanding product coverage in local medical institutions and promoting high-altitude medical products.
- Research and Development: Developing high-altitude medical products and collaborating with research institutions to address common high-altitude diseases.
- Sustainable Supply Chain: Ensuring a secure, stable, and sustainable supply chain for medicinal materials, with a total cultivated area of 502,450 mu across various ecological zones.
Conclusion
Tibet Cheezheng Tibetan Medicine Co Ltd continues to strengthen its position as a leader in the Tibetan medicine industry, leveraging strategic expansions, collaborations, and a focus on sustainable practices to drive growth and innovation.